The speed of the creation of vaccines for the SARS-CoV-2 virus that causes COVID-19 was a modern marvel. You might already have already gotten yours, a little more than a year after the virus overtook the planet. But what if vaccines and therapeutics could emerge even faster in response to the next pandemic?
Thats one of the goals of a $5 million gift from Microsoft to the Institute for Protein Design at the University of Washington School of Medicine. The funding will be used to find new ways to apply artificial intelligence to protein design. One result, they hope, will be faster creation of therapeutics and vaccines in the next pandemic.
On this episode of the GeekWire Health Tech Podcast, we talk with Microsofts chief scientific officer, Eric Horvitz, and the director of the UW institute, David Baker, about their collaboration, and their aspirations for the new age of artificial intelligence and biotechnology.
In general, my feeling has been for three decades that AI generally, including machine learning, is a sleeping giant in healthcare, both in the biosciences as well as in in clinical medicine, Horvitz said. And I think were seeing the waking of that sleeping giant now.
Its the latest stage in the evolution of UW Medicines Institute for Protein Design, which focuses on the creation of de novo proteins, made from scratch rather than derived from nature. Proteins are molecules that carry out the critical functions in our bodies and all living things.
If you take a protein that exists in nature, and you adapt it as a therapeutic, its never really perfect, Baker said. It didnt evolve for that purpose.
However, he explained, if you can make things from scratch, then you really can put in all the properties you want, and leave out all the properties you dont want. And then as machine learning gains steam in this area, and the capabilities grow and grow, I think it will be real game-changer.
As an example of the potential, one of Bakers colleagues at the Institute for Protein Design, Neil King, has designed COVID-19 vaccine candidates that appear to be more potent than those currently in use. Those vaccine candidates are currently undergoing clinical trials.
In announcing the gift, Microsoft and UW Medicine said they will start by identifying areas where neural networks and large-scale computing can be applied to protein design, and then collaborate on the development and manufacturing of new proteins for testing in the UW Medicine lab.
The implications of this new era of AI and protein design go beyond vaccines and pandemics, Baker said. What Id encourage everyone to think about is, now that we can design proteins with intent, what is possible? he said. I think were really just limited by our imaginations.
Listen above or subscribe to GeekWire Health Tech in any podcast app.